nelarabine
novartis
['leusm', 'elara', 'nelarabine']
disappointing rates of mrd response w/ nelarabine for molecular failure; early t-all remains most challenging subgroup; need to use facs for mrd as well given lack of suitable mol mrd target in some pts (esp early t). #ash22 #leusm #allsm (2/2)
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????